Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma
Ignacio Duran, MD
Sandy Srinivas, MD
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Rana McKay, MD
Testosterone Revisited: Importance of Monitoring and Impact of Rebound on Quality of Life in Advanced Prostate Cancer
Tanya Dorff, MD
Treating R/R Classic Hodgkin Lymphoma: Ipilimumab and Other Approaches
Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
Heather Greenlee, ND, PhD, MPH
The Potential Link Between COVID-19 and Cancer Regression
Ankit Bharat, MD
Understanding iMCD Through RNA Sequencing
Michael Gonzalez, PhD, MSc
The Future of ITP Care: Exploring New Treatments
Michele Lambert, MD, MSTR
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker
Jacob Sands, MD
Marina Garassino, MD
Diagnosing Castleman Disease: Key Considerations
Mateo Bustamante
Revolutionizing Breast Cancer Care: The Emerging Role of Liquid Biopsy Technologies
Heather A. Parsons, MD, MPH
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Joshua Brandstadter, MD, PhD, MSc
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
Luis Paz-Ares, MD, PhD
Helena Yu, MD
Matthew Gubens, MD, MS
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.